ReviewCancer drug resistance (Alhambra, Calif.)2022

Molecular vulnerabilities and therapeutic resistance in hormone receptor positive and HER2 dependent breast cancer tumours.

Ravi Velaga et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.